Research and development daily Myovant publishes data on clinical failure of Stage 3 of Relugolix prostate cancer.

2020.09.30 Research and Development NEWS: Preliminary clinical results of the new crown and antibody therapy; "first-in-class" therapy is eligible for FDA priority review for the treatment of fatal type A MoCD; Dittoxi monoanti and Zebutini in Baiji Shenzhou are to be included in the priority review; Dupreyu monoantitor in China after approval of the second listing application ...... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) Myovant released relugolix prostate cancer phase 3 clinical failure data 29, Myovant announced the evaluation of patients with advanced prostate cancer to receive relugolix treatment phase 3 clinical study HERO secondary endpoint results.
the study showed that relugolix did not have a statistical advantage in treating the despotic resistance survival rate of patients with metastatic prostate cancer for 48 weeks compared to the gontheproof hormone drug acetate.
Regeneratives: Preliminary clinical results of neo-coronary neutral antibody therapy Regeneratives published preliminary descriptive data obtained in the seamless Phase 1/2/3 clinical trial of regenerative antibody cocktail therapy REGEN-COV2 for its research new coronavirus neutrality.
data show that REN-COV2 reduces viral load and reduces the time required for symptom relief when treating non-hospitalized COVID-19 patients.
reGEN-COV2 also showed a positive trend in reducing patient visits to hospitals.
ironwood Pharmaceuticals announced it was suspending the development of its refroutable gastroesoesic reflow disease (GERD) drug, IW-3718.
comes after Ironwood reviewed non-blind data from phase III clinical trialS IW-3718-302 of the company's GERD drug, which failed to reduce heartburn in patients.
"First-in-class" therapy has been approved by the FDA for priority review of the treatment of the deadly MoCD BridgeBio and its subsidiary Origin announced that the FDA has accepted and granted priority review eligibility for a new drug for fosdenopterin.
Fosdenopterin is a "first-in-class" cPMP hydrobromohydrate hydrate hydrate.
as a cyclophosphate substrate replacement therapy for the treatment of patients with type A cofactor deficiency (MoCD).
JNJ-61186372 injection into CDE "proposed breakthrough therapy" public announcement 29, Johnson and Johnson JNJ-61186372 injection was included in CDE The "proposed breakthrough therapeutic drug variety" is publicly available for the treatment of patients with metastasis or surgically indistinguable NSCLC patients who progress during or after platinum-containing double-drug chemotherapy or who are insirable to the EGFR20 exon insertion mutation.
Pharmaceutical TAK-788 capsules to be included in the breakthrough therapy CDE to be included in the breakthrough therapy column update on the 29th, Takeda Pharmaceuticals TAK-788 capsules to be included.
TAK 788 is a small molecular inhibitor with oral activity targeting EGFR and HER2 mutations and is selective for wild type EGFR.
is the first new drug to have a breakthrough effect on EGFR 20 exon insertion mutations.
Huahai Pharmaceutical HB002.1M was approved 3 clinical 28, Huahai Pharmaceuticals issued a notice that subsidiary Huabo Bio's recombinant human vascular endotrial growth factor subject - antibody fusion protein eye injection (HB002.1M) project 3 new adaptations, approved by the State Drug Administration clinical.
To date, HB002.1M has four adaptation disorders (wet age-related macular degeneration, retinal branch vein blockage secondary macular edema, retinal central venous blockage secondary macular edema and diabetic macular edema) approved for clinical use.
the first adaptive wet age-related macular degeneration trial with HB002.1M has progressed to Phase II clinical.
PCCW biopropypol medium/long-chain fat emulsion is expected to be the first to be evaluated recently, Jiangsu PCCW bio by imitation 4 categories of reported propofol medium/long-chain fat milk injection (receiving number CYHS1900274) registration status changed to "in approval", is expected to be approved and the first review.
Asaan Pharmaceutical Oribatinib tablets to be priority review 29, CDE official website shows that Asaan Pharmaceuticals wholly-owned subsidiary Guangzhou Shunjian Biopharmaceutical Technology Co., Ltd. submitted a class 1 new drug "Oribatini tablets" proposed Included in the priority review, the adaptation is used in adult patients with chronic myeloid leukemia (CML) or accelerated period (AP) with T315I mutations after resistance to any tyrosine kinase inhibitor.
, Dittoxi monoanti and Zebutini to be included in the priority review CDE 29 public announcement, Baiji Shenzhou 2 new drugs to be included in the priority review.
one of these is a ditoxidant injection, which is being developed to treat a variety of neuroblastomas.
according to public information, this is the monoclonal antibody QARZIBA, introduced from EUSA Pharma in Baiji Shenzhou earlier this year, which can bind to GD2.iii, a specific target for overexposed neuroblastoma cells.
the other is the BTK inhibitor Zebutinib capsule, which is included in the priority review of the adaptation: suitable for the treatment of adult patients with fahrenheit globulinemia.
the second listing application submitted by Sanofi du Priyu monoantigen in China after it was approved in March was accepted by CDE, just about three months after the drug was first approved in China.
was approved by the NMPA in June this year for the treatment of adults with moderate to severe endexual dermatitis with poor control of prescription drugs for external use or not recommended for use with prescription drugs for use in adolescents and adults 12 years of age and older.
.